<DOC>
	<DOCNO>NCT00271505</DOCNO>
	<brief_summary>The goal clinical research study evaluate effectiveness Avastin® combination docetaxel carboplatin treatment lung cancer . The safety combination also study .</brief_summary>
	<brief_title>Avastin/Docetaxel/Carboplatin Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Avastin® humanize monoclonal antibody bind vascular endothelial growth factor ( VEGF ) . VEGF play important role growth normal abnormal blood vessel . Avastin® design prevent slow growth cancer cell block effect VEGF . Docetaxel carboplatin standard chemotherapy drug approve FDA treatment NSCLC . Docetaxel carboplatin design work stop division cancer cell . If find eligible , begin receive Avastin® , docetaxel , carboplatin . Avastin® , carboplatin , docetaxel give vein every 3 week . The first dose Avastin® give 90 minute . The second dose Avastin® give 60 minute . All dose Avastin® give 30 minute . Carboplatin docetaxel always give 30 minute . They give day every 3 week ( 1 cycle ) . You may receive 6 cycle treatment . You receive standard premedication dexamethasone help decrease risk side effect . Dexamethasone take receive docetaxel infusion . During study , blood test ( 2 teaspoon ) every 3 week look blood count . These sample use routine lab test . You see physician every 3 week give physical exam . Your blood pressure monitor , ask side effect experience . A performance status evaluation also do . In addition , urine test every 2 cycle treatment . After 2 cycle treatment ( 6 week ) , chest x-ray computerized tomography ( CT ) magnetic resonance imaging ( MRI ) scan evaluate status disease . These repeat every 2 cycle . Your continued participation study depend cancer responds study drug . Your doctor may decide take study experience significant side effect medical condition worsens . You may continue receive bevacizumab long cancer respond study treatment . You followed-up phone routine clinic visit least 12 month monitor condition disease status . This investigational study . Avastin® approve FDA treatment colorectal cancer . Docetaxel carboplatin FDA approve commercially available . The use drug together study experimental . A total 50 patient take part study . All participant enrol M. D. Anderson .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Men woman , least 18 year old , histologically confirm , advanced stage IIIB IV NSCLC curative option exist docetaxel carboplatin reasonable treatment option ; 2 . At least 1 target lesion unidimensionally measurable define Response Evaluation Criteria Solid Tumors ( RECIST ) previously irradiate ; 3 . Eastern Cooperative Oncology Group Performance Status 0 1 , ( determine within 2 week prior receive study medication ; 4 . Ability understand adhere protocol requirement , give informed consent 5 . Use effective mean contraception ( men woman ) subject childbearing potential . Childbearing potential defined follow : A woman childbearing potential sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . 1 . Patients docetaxel nonradiosensitizing therapy 2 . Patients receive prior full dose systemic chemotherapy NSCLC ( ie neoadjuvant , adjuvant , metastatic ) within last 6 month . 3 . ECOG status 2 great 4 . Screening clinical laboratory value : *ANC &lt; 1,500/µL *Platelet count &lt; 75,000/µL * INR &gt; /= 1.5 *T bilirubin elevation normal ( MDACC upper normal limit 1.0 mg/dL ) *Serum creatinine &gt; 2.0 mg/dL *Hemoglobin &lt; 9 mg/dL ( may transfuse receive epoetin alfa [ e.g. , Epogen® ] maintain exceed level ) *The pt ineligible : 1.alk phos &gt; 5xULN ; 2.AST ALT &gt; 5xULN ; 3.alk phos &gt; 1xULN &lt; /= 2.5xULN AND AST ALT &gt; 1.5xULN &lt; /=5xULN ; 4.alk phos &gt; 2.5xULN &lt; /=5xULN AND AST ALT &gt; 1xULN &lt; /= 1.5xULN ; 5.alk phos &gt; 2.5xULN &lt; /=5xULN AND AST ALT &gt; 1.5xULN &lt; /=5xULN 5 . Inability comply study and/or followup procedure 6 . History disease , active infection , metabolic dysfunction , physical examination finding , clinical laboratory find uncontrolled require medical intervention give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication . 7 . Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study bevacizumab cancer study 8 . Prior exposure antiVEGF therapy 9 . Blood pressure &gt; 140/90 mmHg document two consecutive blood pressure reading within 4 hour 10 . Any prior history hypertensive crisis hypertensive encephalopathy 11 . New York Heart Association ( NYHA ) Grade II great congestive heart failure 12 . History myocardial infarction unstable angina within 6 month 13 . History stroke transient ischemic attack within 6 month 14 . Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) 15 . Evidence bleed diathesis coagulopathy 16 . Presence central nervous system brain metastasis time 17 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study 18 . Minor surgical procedure , fine needle aspiration core biopsy within 7 day prior Day 0 19 . Pregnant ( positive pregnancy test ) lactate 20 . Proteinuria screen demonstrate either : Urine protein : creatinine ( UPC ) ratio &gt; 1.0 screening OR Urine dipstick proteinuria &gt; 2+ ( patient discover &gt; 2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate &lt; 1g protein 24 hour eligible ) . 21 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 0 22 . Serious , nonhealing wound , ulcer , bone fracture 23 . Lung carcinoma squamous cell histology histology close proximity major vessel , cavitation . 24 . History hemoptysis ( bright red blood 1/2 teaspoon ) 25 . Full dose anticoagulation , chronic use Aspirin ( &gt; 325 mg/day ) NSAIDs 26 . Inability comply study and/or followup procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Avastin</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Anti-VEGF monoclonal antibody</keyword>
	<keyword>rhuMAb-VEGF</keyword>
	<keyword>Paraplatin®</keyword>
	<keyword>Taxotere</keyword>
</DOC>